The clusterin paradigm in prostate and breast carcinogenesis

Endocrine-Related Cancer

Volumn 17, Issue 1, 2010, Pages

  Rizzi, Federica ^a,b   Bettuzzi, Saverio ^a,b  

^a UNIVERSITY OF PARMA   (Italy)

^b NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CATECHIN; CELL PROTEIN; CLUSTERIN; DOCETAXEL; GREEN TEA EXTRACT; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OGX 011; ONCOPROTEIN; PACLITAXEL; PLACEBO; TOREMIFENE;

ADJUVANT THERAPY; ANTISENSE THERAPY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CLINICAL TRIAL; CLU GENE; CYTOPLASM; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; HUMAN; HYPOTHESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; TEA; TUMOR CELL; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BREAST NEOPLASMS; CATECHIN; CELL TRANSFORMATION, NEOPLASTIC; CLUSTERIN; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; ONCOGENES; ORCHIECTOMY; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77449142191     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0140     Document Type: Review

References (140)

1. Andersen CL, Schepeler T, Thorsen K, Birkenkamp-Demtroder K, Mansilla F, Aaltonen LA, Laurberg S & Orntoft TF 2007 Clusterin expression in normal mucosa and colorectal cancer. Molecular & Cellular Proteomics 6 1039-1048.
2. Astancolle S, Guidetti G, Pinna C, Corti A & Bettuzzi S 2000 Increased levels of clusterin (SGP-2) mRNA and protein accompany rat ventral prostate involution following finasteride treatment. Journal of Endocrinology 167 197-204.
3. Bailey RW, Dunker AK, Brown CJ, Garner EC & Griswold MD 2001 Clusterin, a binding protein with a molten globule-like region. Biochemistry 40 11828-11840.
4. Bettuzzi S, Hiipakka RA, Gilna P & Liao ST 1989 Identification of an androgen-repressed mRNA in rat ventral prostate as coding for sulphated glycoprotein 2 by cDNA cloning and sequence analysis. Biochemical Journal 257 293-296.
5. Bettuzzi S, Davalli P, Astancolle S, Carani C, Madeo B, Tampieri A & Corti A 2000 Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens. Cancer Research 60 28-34.
6. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G & Corti A 2006 Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Research 66 1234-1240.
7. Bettuzzi S, Davalli P, Davoli S, Chayka O, Rizzi F, Belloni L, Pellacani D, Fregni G, Astancolle S, Fassan M et al. 2009 Genetic inactivation of ApoJ/clusterin: effects on prostate tumourigenesis and metastatic spread. Oncogene [in press].
8. Blaschuk O, Burdzy K & Fritz IB 1983 Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. Journal of Biological Chemistry 258 7714-7720.
9. Brausi M, Rizzi F & Bettuzzi S 2008 Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. European Urology 54 472-473.
10. Burkey BF, deSilva HV & Harmony JA 1991 Intracellular processing of apolipoprotein J precursor to the mature heterodimer. Journal of Lipid Research 32 1039-1048.
11. Caccamo AE, Scaltriti M, Caporali A, D'Arca D, Scorcioni F, Candiano G, Mangiola M & Bettuzzi S 2003 Nuclear translocation of a clusterin isoform is associated with induction of anoikis in SV40-immortalized human prostate epithelial cells. Annals of the New York Academy of Sciences 1010 514-519.
12. 2+ depletion induces nuclear clusterin, a novel effector of apoptosis in immortalized human prostate cells. Cell Death and Differentiation 12 101-104.
13. Caporali A, Davalli P, Astancolle S, D'Arca D, Brausi M, Bettuzzi S & Corti A 2004 The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis 25 2217-2224.
14. Cappelletti V, Gariboldi M, De Cecco L, Toffanin S, Reid JF, Lusa L, Bajetta E, Celio L, Greco M, Fabbri A et al. 2008 Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptorpositive breast cancer. Endocrine-Related Cancer 15 439-449.
15. Cervellera M, Raschella G, Santilli G, Tanno B, Ventura A, Mancini C, Sevignani C, Calabretta B & Sala A 2000 Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB. Journal of Biological Chemistry 275 21055-21060.
16. Chayka O, Corvetta D, Dews M, Caccamo AE, Piotrowska I, Santilli G, Gibson S, Sebire NJ, Himoudi N, Hogarty MD et al. 2009 Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas. Journal of the National Cancer Institute 101 663-677.
17. Chen T, Turner J, McCarthy S, Scaltriti M, Bettuzzi S & Yeatman TJ 2004 Clusterin-mediated apoptosis is regulated by adenomatous polyposis coli and is p21 dependent but p53 independent. Cancer Research 64 7412-7419.
18. Cheng CY, Chen CL, Feng ZM, Marshall A & Bardin CW 1988 Rat clusterin isolated from primary Sertoli cell-enriched culture medium is sulfated glycoprotein-2 (SGP-2). Biochemical and Biophysical Research Communications 155 398-404.
19. Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D & Gleave ME 2005 A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. Journal of the National Cancer Institute 97 1287-1296.
20. Chi KN, Siu LL, Hirte H, Hotte SJ, Knox J, Kollmansberger C, Gleave M, Guns E, Powers J, Walsh W et al. 2008 A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clinical Cancer Research 14 833-839.
21. Chia S, Dent S, Ellard S, Ellis PM, Vandenberg T, Gelmon K, Powers J, Walsh W, Seymour L & Eisenhauer EA 2009 Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. Clinical Cancer Research 15 708-713.
22. Choi NH, Mazda T & Tomita M 1989 A serum protein SP40,40 modulates the formation of membrane attack complex of complement on erythrocytes. Molecular Immunology 26 835-840.
23. Choi-Miura NH, Takahashi Y, Nakano Y, Tobe T&TomitaM 1992 Identification of the disulfide bonds in human plasma protein SP-40,40 (apolipoprotein-J). Journal of Biochemistry 112 557-561.
24. Cochrane DR, Wang Z, Muramaki M, Gleave ME & Nelson CC 2007 Differential regulation of clusterin and its isoforms by androgens in prostate cells. Journal of Biological Chemistry 282 2278-2287.
25. Collard MW & Griswold MD 1987 Biosynthesis and molecular cloning of sulfated glycoprotein 2 secreted by rat Sertoli cells. Biochemistry 26 3297-3303.
26. Criswell T, BemanM, Araki S, Leskov K, Cataldo E, Mayo LD & Boothman DA 2005 Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/ Egr-1 signaling regulates clusterin expression, a pro-survival factor. Journal of Biological Chemistry 280 14212-14221.
27. Devauchelle V, Essabbani A, De Pinieux G, Germain S, Tourneur L, Mistou S, Margottin-Goguet F, Anract P, Migaud H, Le Nen D et al. 2006 Characterization and functional consequences of underexpression of clusterin in rheumatoid arthritis. Journal of Immunology 177 6471-6479.
28. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA & Chinnaiyan AM 2001 Delineation of prognostic biomarkers in prostate cancer. Nature 412 822-826.
29. Dhanasekaran SM, Dash A, Yu J, Maine IP, Laxman B, Tomlins SA, Creighton CJ, Menon A, Rubin MA & Chinnaiyan AM 2005 Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty. FASEB Journal 19 243-245.
30. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A et al. 2008 Stromal gene expression predicts clinical outcome in breast cancer. Nature Medicine 14 518-527.
31. Fischer-Colbrie R, Zangerle R, Frischenschlager I, Weber A & Winkler H 1984 Isolation and immunological characterization of a glycoprotein from adrenal chromaffin granules. Journal of Neurochemistry 42 1008-1016.
32. French LE, Chonn A, Ducrest D, Baumann B, Belin D, Wohlwend A, Kiss JZ, Sappino AP, Tschopp J & Schifferli JA 1993 Murine clusterin: molecular cloning and mRNA localization of a gene associated with epithelial differentiation processes during embryogenesis. Journal of Cell Biology 122 1119-1130.
33. Fritz IB, Burdzy K, Setchell B & Blaschuk O 1983 Ram rete testis fluid contains a protein (clusterin) which influences cell-cell interactions in vitro. Biology of Reproduction 28 1173-1188.
34. Gleave M & Miyake H 2005 Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World Journal of Urology 23 38-46.
35. Gonzalez-Angulo AM, Morales-Vasquez F & Hortobagyi GN 2007 Overview of resistance to systemic therapy in patients with breast cancer. Advances in Experimental Medicine and Biology 608 1-22.
36. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ & Rosen JM 1995 Prostate cancer in a transgenic mouse. PNAS 92 3439-3443.
37. Gupta S, Hastak K, Ahmad N, Lewin JS & Mukhtar H 2001 Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. PNAS 98 10350-10355.
38. Hellebrekers DM, Melotte V, Vire E, Langenkamp E, Molema G, Fuks F, Herman JG, Van Criekinge W, Griffioen AW & van Engeland M 2007 Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Research 67 4138-4148.
39. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P et al. 2004 Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgenresponsive genes and mechanisms of therapy resistance. American Journal of Pathology 164 217-227.
40. Horton P, Park KJ, Obayashi T, Fujita N, Harada H, Adams-Collier CJ & Nakai K 2007 WoLF PSORT: protein localization predictor. Nucleic Acids Research 35 W585-W587.
41. Humphreys DT, Carver JA, Easterbrook-Smith SB & Wilson MR 1999 Clusterin has chaperone-like activity similar to that of small heat shock proteins. Journal of Biological Chemistry 274 6875-6881.
42. ItahanaY, Piens M, Sumida T, Fong S,Muschler J&Desprez PY 2007 Regulation of clusterin expression in mammary epithelial cells. Experimental Cell Research 313 943-951.
43. James RW, Hochstrasser AC, Borghini I, Martin B, Pometta D & Hochstrasser D 1991 Characterization of a human high density lipoprotein-associated protein, NA1/NA2. Identity with SP-40,40, an inhibitor of complement-mediated cytolysis. Arteriosclerosis, Thrombosis, and Vascular Biology 11 645-652.
44. Jenne DE & Tschopp J 1989 Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid. PNAS 86 7123-7127.
45. Jian L, Xie LP, Lee AH & Binns CW 2004 Protective effect of green tea against prostate cancer: a case-control study in southeast China. International Journal of Cancer 108 130-135.
46. Jin G & Howe PH 1999 Transforming growth factor beta regulates clusterin gene expression via modulation of transcription factor c-Fos. European Journal of Biochemistry 263 534-542.
47. Jordan-Starck TC, Lund SD, Witte DP, Aronow BJ, Ley CA, Stuart WD, Swertfeger DK, Clayton LR, Sells SF, Paigen B et al. 1994 Mouse apolipoprotein J: characterization of a gene implicated in atherosclerosis. Journal of Lipid Research 35 194-210.
48. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL & Gleave ME 2002 Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 50 179-188.
49. Kang SW, Shin YJ, Shim YJ, Jeong SY, Park IS & Min BH 2005 Clusterin interacts with SCLIP (SCG10-like protein) and promotes neurite outgrowth of PC12 cells. Experimental Cell Research 309 305-315.
50. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster BA & Greenberg NM 2003 Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 55 219-237.
51. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, RichardsonAL, PolyakK, Tubo R& Weinberg RA 2007 Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449 557-563.
52. Khan N, Afaq F, Saleem M, Ahmad N & Mukhtar H 2006 Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Research 66 2500-2505.
53. Kirszbaum L, Sharpe JA, Murphy B, d'Apice AJ, Classon B, Hudson P & Walker ID 1989 Molecular cloning and characterization of the novel, human complement-associated protein, SP-40,40: a link between the complement and reproductive systems. EMBO Journal 8 711-718.
54. Kirszbaum L, Bozas SE & Walker ID 1992 SP-40,40, a protein involved in the control of the complement pathway, possesses a unique array of disulphide bridges. FEBS Letters 297 70-76.
55. Klock G, Storch S, Rickert J, Gutacker C & Koch-Brandt C 1998 Differential regulation of the clusterin gene by Ha-ras and c-myc oncogenes and during apoptosis. Journal of Cellular Physiology 177 593-605.
56. Klokov D, Criswell T, Leskov KS, Araki S, Mayo L & Boothman DA 2004 IR-inducible clusterin gene expression: a protein with potential roles in ionizing radiation-induced adaptive responses, genomic instability, and bystander effects. Mutation Research 568 97-110.
57. Kruger S, Ola V, Fischer D, Feller AC & Friedrich M 2007 Prognostic significance of clusterin immunoreactivity in breast cancer. Neoplasia 54 46-50.
58. Kyprianou N, English HF, Davidson NE & Isaacs JT 1991 Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Research 51 162-166.
59. Lakins JN, Poon S, Easterbrook-Smith SB, Carver JA, Tenniswood MP & Wilson MR 2002 Evidence that clusterin has discrete chaperone and ligand binding sites. Biochemistry 41 282-291.
60. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U et al. 2004 Gene expression profiling identifies clinically relevant subtypes of prostate cancer. PNAS 101 811-816.
61. LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V & Gerald WL 2002 Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Research 62 4499-4506.
62. Law GL & Griswold MD 1994 Activity and form of sulfated glycoprotein 2 (clusterin) from cultured Sertoli cells, testis, and epididymis of the rat. Biology of Reproduction 50 669-679.
63. Lee C, Atanelov L, Modrek B & Xing Y 2003 ASAP: the Alternative Splicing Annotation Project. Nucleic Acids Research 31 101-105.
64. Leskov KS, Criswell T, Antonio S, Li J, Yang CR, Kinsella TJ & Boothman DA 2001 When X-ray-inducible proteins meet DNA double strand break repair. Seminars in Radiation Oncology 11 352-372.
65. Leskov KS, Klokov DY, Li J, Kinsella TJ & Boothman DA 2003 Synthesis and functional analyses of nuclear clusterin, a cell death protein. Journal of Biological Chemistry 278 11590-11600.
66. Li X, Massa PE, Hanidu A, Peet GW, Aro P, Savitt A, Mische S, Li J & Marcu KB 2002 IKKalpha, IKKbeta, and NEMO/IKKgamma are each required for the NF-kappa B-mediated inflammatory response program. Journal of Biological Chemistry 277 45129-45140.
67. Loison F, Debure L, Nizard P, le Goff P, Michel D & le Drean Y 2006 Up-regulation of the clusterin gene after proteotoxic stress: implication of HSF1-HSF2 heterocomplexes. Biochemical Journal 395 223-231.
68. Lund P, Weisshaupt K, Mikeska T, Jammas D, Chen X, Kuban RJ, Ungethum U, Krapfenbauer U, Herzel HP, Schafer R et al. 2006 Oncogenic HRAS suppresses clusterin expression through promoter hypermethylation. Oncogene 25 4890-4903.
69. Luo JH, Yu YP, Cieply K, Lin F, Deflavia P, Dhir R, Finkelstein S, Michalopoulos G & Becich M 2002 Gene expression analysis of prostate cancers. Molecular Carcinogenesis 33 25-35.
70. Mallory JC, Crudden G, Oliva A, Saunders C, Stromberg A & Craven RJ 2005 A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells. Molecular Pharmacology 68 1747-1756.
71. Markopoulou S, Kontargiris E, Batsi C, Tzavaras T, Trougakos I, Boothman DA, Gonos ES & Kolettas E 2009 Vanadium-induced apoptosis of HaCaT cells is mediated by c-fos and involves nuclear accumulation of clusterin. FEBS Journal.
72. McLaughlin L, Zhu G, Mistry M, Ley-Ebert C, Stuart WD, Florio CJ, Groen PA, Witt SA, Kimball TR, Witte DP et al. 2000 Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis. Journal of Clinical Investigation 106 1105-1113.
73. Michel D, Gillet G, Volovitch M, Pessac B, Calothy G & Brun G 1989 Expression of a novel gene encoding a 51.5 kD precursor protein is induced by different retroviral oncogenes in quail neuroretinal cells. Oncogene Research 4 127-136.
74. Michel D, Chatelain G, North S & Brun G 1997 Stressinduced transcription of the clusterin/apoJ gene. Biochemical Journal 328 45-50.
75. Miyake H, Chi KN & Gleave ME 2000a Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgenindependent PC-3 prostate cancer cells both in vitro and in vivo. Clinical Cancer Research 6 1655-1663.
76. Miyake H, Nelson C, Rennie PS & Gleave ME 2000b Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Research 60 170-176.
77. Miyake H, Nelson C, Rennie PS & Gleave ME 2000c Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Research 60 2547-2554.
78. Montpetit ML, Lawless KR & Tenniswood M 1986 Androgen-repressed messages in the rat ventral prostate. Prostate 8 25-36.
79. Moretti RM, Marelli MM, Mai S, Cariboni A, Scaltriti M, Bettuzzi S & Limonta P 2007 Clusterin isoforms differentially affect growth and motility of prostate cells: possible implications in prostate tumorigenesis. Cancer Research 67 10325-10333.
80. Morris EJ, Ji JY, Yang F, Di Stefano L, Herr A, Moon NS, Kwon EJ, Haigis KM, Naar AM & Dyson NJ 2008 E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8. Nature 455 552-556.
81. Murphy BF, Kirszbaum L, Walker ID & d'Apice AJ 1988 SP-40,40, a newly identified normal human serum protein found in the SC5b-9 complex of complement and in the immune deposits in glomerulonephritis. Journal of Clinical Investigation 81 1858-1864.
82. Nizard P, Tetley S, Le Drean Y, Watrin T, Le Goff P, Wilson MR & Michel D 2007 Stress-induced retrotranslocation of clusterin/ApoJ into the cytosol. Traffic 8 554-565.
83. Nuutinen T, Suuronen T, Kyrylenko S, Huuskonen J & Salminen A 2005 Induction of clusterin/apoJ expression by histone deacetylase inhibitors in neural cells. Neurochemistry International 47 528-538.
84. O'ryan MK, Baker HW, Saunders JR, Kirszbaum L, Walker ID, Hudson P, Liu DY, Glew MD, d'Apice AJ & Murphy BF 1990 Human seminal clusterin (SP-40,40). Isolation and characterization. Journal of Clinical Investigation 85 1477-1486.
85. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA et al. 2000 Molecular portraits of human breast tumours. Nature 406 747-752.
86. Pins MR, Fiadjoe JE, Korley F, Wong M, Rademaker AW, Jovanovic B, Yoo TK, Kozlowski JM, Raji A, Yang XJ et al. 2004 Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report. Prostate Cancer and Prostatic Disease 7 243-248.
87. Poon S, Easterbrook-Smith SB, Rybchyn MS, Carver JA & Wilson MR 2000 Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state. Biochemistry 39 15953-15960.
88. Pucci S, Bonanno E, Pichiorri F, Angeloni C & Spagnoli LG 2004 Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 23 2298-2304.
89. Radvanyi L, Singh-Sandhu D, Gallichan S, Lovitt C, Pedyczak A, Mallo G, Gish K, Kwok K, Hanna W, Zubovits J et al. 2005 The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. PNAS 102 11005-11010.
90. Ranney MK, Ahmed IS, Potts KR & Craven RJ 2007 Multiple pathways regulating the anti-apoptotic protein clusterin in breast cancer. Biochimica et Biophysica Acta 1772 1103-1111.
91. Rauhala HE, Porkka KP, Saramaki OR, Tammela TL & Visakorpi T 2008 Clusterin is epigenetically regulated in prostate cancer. International Journal of Cancer 123 1601-1609.
92. Reddy KB, Jin G, Karode MC, Harmony JA & Howe PH 1996 Transforming growth factor beta (TGF beta)-induced nuclear localization of apolipoprotein J/clusterin in epithelial cells. Biochemistry 35 6157-6163.
93. Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M & Petito CK 2000 Overexpression of clusterin in human breast carcinoma. American Journal of Pathology 157 393-399.
94. Redondo M, Tellez T, Roldan MJ, Serrano A, Garcia-Aranda M, Gleave ME, Hortas ML & Morell M 2007 Anticlusterin treatment of breast cancer cells increases the sensitivities of chemotherapy and tamoxifen and counteracts the inhibitory action of dexamethasone on chemotherapy-induced cytotoxicity. Breast Cancer Research 9 R86.
95. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A & Chinnaiyan AM 2004 ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6 1-6.
96. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM & Ganesan S 2006 X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9 121-132.
97. Rizzi F, Belloni L, Crafa P, Lazzaretti M, Remondini D, Ferretti S, Cortellini P, Corti A & Bettuzzi S 2008 A novel gene signature for molecular diagnosis of human prostate cancer by RT-qPCR. PLoS ONE 3 e3617.
98. Rizzi F, Caccamo AE, Belloni L & Bettuzzi S 2009a Clusterin is a short half-life, poly-ubiquitinated protein, which controls the fate of prostate cancer cells. Journal of Cellular Physiology 219 314-323.
99. Rizzi F, Troglio MG, Brausi M & Bettuzzi S 2009b Clusterin gene expression as a novel biomarker of response with GTE in humans. European Urology Supplements 8 345.
100. Rosenberg ME & Silkensen J 1995 Clusterin: physiologic and pathophysiologic considerations. International Journal of Biochemistry and Cell Biology 27 633-645.
101. Sallman DA, Chen X, Zhong B, Gilvary DL, Zhou J, Wei S & Djeu JY 2007 Clusterin mediates TRAIL resistance in prostate tumor cells. Molecular Cancer Therapeutics 6 2938-2947.
102. Santilli G, Aronow BJ & Sala A 2003 Essential requirement of apolipoprotein J (clusterin) signaling for IkappaB expression and regulation of NF-kappaB activity. Journal of Biological Chemistry 278 38214-38219.
103. Savkovic V, Gantzer H, Reiser U, Selig L, Gaiser S, Sack U, Kloppel G, Mossner J, Keim V, Horn F et al. 2007 Clusterin is protective in pancreatitis through anti-apoptotic and anti-inflammatory properties. Biochemical and Biophysical Research Communications 356 431-437.
104. Scaltriti M, Brausi M, Amorosi A, Caporali A, D'Arca D, Astancolle S, Corti A & Bettuzzi S 2004a Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer. International Journal of Cancer 108 23-30.
105. Scaltriti M, Santamaria A, Paciucci R & Bettuzzi S 2004b Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells1. Cancer Research 64 6174-6182.
106. Scaltriti M, Belloni L, Caporali A, Davalli P, Remondini D, Rizzi F, Astancolle S, Corti A & Bettuzzi S 2006 Molecular classification of green tea catechin-sensitive and green tea catechin-resistant prostate cancer in the TRAMP mice model by quantitative real-time PCR gene profiling. Carcinogenesis 27 1047-1053.
107. Schepeler T, Mansilla F, Christensen LL, Orntoft TF & Andersen CL 2007 Clusterin expression can be modulated by changes in TCF1-mediated Wnt signaling. Journal of Molecular Signaling 2 6.
108. Shannan B, Seifert M, Leskov K, Willis J, Boothman D, Tilgen W & Reichrath J 2006 Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death and Differentiation 13 12-19.
109. Shukla S, MacLennan GT, Fu P, Patel J, Marengo SR, Resnick MI & Gupta S 2004 Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia 6 390-400.
110. Shukla S, Maclennan GT, Marengo SR, Resnick MI & Gupta S 2005 Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. Prostate 64 224-239.
111. de Silva HV, Harmony JA, Stuart WD, Gil CM & Robbins J 1990a Apolipoprotein J: structure and tissue distribution. Biochemistry 29 5380-5389.
112. de Silva HV, Stuart WD, Park YB, Mao SJ, Gil CM, Wetterau JR, Busch SJ & Harmony JA 1990b Purification and characterization of apolipoprotein. Journal of Biological Chemistry 265 14292-14297.
113. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP et al. 2002 Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1 203-209.
114. So A, Sinnemann S, Huntsman D, Fazli L & Gleave M 2005 Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Molecular Cancer Therapeutics 4 1837-1849.
115. Sørlie T, PerouCM, Tibshirani R, Aas T, Geisler S, Johnson H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98 10869-10874.
116. Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A & Gleave ME 2008 Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. British Journal of Urolgy International 102 389-397.
117. Sporn MB, Dunlop NM, Newton DL & Smith JM 1976 Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Federation Proceedings 35 1332-1338.
118. Suh J & Rabson AB 2004 NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? Journal of Cellular Biochemistry 91 100-117.
119. Suuronen T, Nuutinen T, Ryhanen T, Kaarniranta K & Salminen A 2007 Epigenetic regulation of clusterin/apolipoprotein J expression in retinal pigment epithelial cells. Biochemical and Biophysical Research Communications 357 397-401.
120. Takase O, Marumo T, Hishikawa K, Fujita T, Quigg RJ & Hayashi M 2008a NF-kappaB-dependent genes induced by proteinuria and identified using DNA microarrays. Clinical and Experimental Nephrology 12 181-188.
121. Takase O, Minto AW, Puri TS, Cunningham PN, Jacob A, Hayashi M & Quigg RJ 2008b Inhibition of NFkappaB-dependent Bcl-xL expression by clusterin promotes albumin-induced tubular cell apoptosis. Kidney International 73 567-577.
122. Thomas-Tikhonenko A, Viard-Leveugle I, Dews M, Wehrli P, Sevignani C, Yu D, Ricci S, el-Deiry W, Aronow B, Kaya G et al. 2004 Myc-transformed epithelial cells down-regulate clusterin, which inhibits their growth in vitro and carcinogenesis in vivo. Cancer Research 64 3126-3136.
123. Toffanin S, Daidone MG, Miodini P, De Cecco L, Gandellini P & Cappelletti V 2008 Clusterin: a potential target for improving response to antiestrogens. International Journal of Oncology 33 791-798.
124. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ et al. 2007 Integrative molecular concept modeling of prostate cancer progression. Nature Genetics 39 41-51.
125. Trougakos IP & Gonos ES 2002 Clusterin/apolipoprotein J in human aging and cancer. International Journal of Biochemistry & Cell Biology 34 1430-1448.
126. Trougakos IP, So A, Jansen B, Gleave ME & Gonos ES 2004 Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Research 64 1834-1842.
127. Turashvili G, Bouchal J, Baumforth K, Wei W, Dziechciarkova M, Ehrmann J, Klein J, Fridman E, Skarda J, Srovnal J et al. 2007 Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 7 55.
128. Vanaja DK, Cheville JC, Iturria SJ & Young CY 2003 Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Research 63 3877-3882.
129. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ et al. 2005 Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8 393-406.
130. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF Jr & Hampton GM 2001 Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Research 61 5974-5978.
131. William WN Jr, Heymach JV, Kim ES & Lippman SM 2009 Molecular targets for cancer chemoprevention. Nature Reviews. Drug Discovery 8 213-225.
132. Wilson MR & Easterbrook-Smith SB 2000 Clusterin is a secreted mammalian chaperone. Trends in Biochemical Sciences 25 95-98.
133. Wong P, Pineault J, Lakins J, Taillefer D, Leger J, Wang C & Tenniswood M 1993 Genomic organization and expression of the rat TRPM-2 (clusterin) gene, a gene implicated in apoptosis. Journal of Biological Chemistry 268 5021-5031.
134. Wong P, Taillefer D, Lakins J, Pineault J, Chader G & Tenniswood M 1994 Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neurodegeneration. European Journal of Biochemistry 221 917-925.
135. Xie MJ, Motoo Y, Su SB, Mouri H, Ohtsubo K, Matsubara F & Sawabu N 2002 Expression of clusterin in human pancreatic cancer. Pancreas 25 234-238.
136. Xie D, Lau SH, Sham JS, Wu QL, Fang Y, Liang LZ, Che LH, Zeng YX & Guan XY 2005 Up-regulated expression of cytoplasmic clusterin in human ovarian carcinoma. Cancer 103 277-283.
137. Yang CR, Leskov K, Hosley-Eberlein K, Criswell T, Pink JJ, Kinsella TJ & Boothman DA 2000 Nuclear clusterin/XIP8, an X-ray-induced Ku70-binding protein that signals cell death. PNAS 97 5907-5912.
138. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S et al. 2004 Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. Journal of Clinical Oncology 22 2790-2799.
139. Zellweger T, Chi K, Miyake H, Adomat H, Kiyama S, Skov K & Gleave ME 2002 Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clinical Cancer Research 8 3276-3284.
140. Zhang LY, Ying WT, Mao YS, He HZ, Liu Y, Wang HX, Liu F, Wang K, Zhang DC, Wang Y et al. 2003 Loss of clusterin both in serum and tissue correlates with the tumorigenesis of esophageal squamous cell carcinoma via proteomics approaches. World Journal of Gastroenterology 9 650-654.